24 September 2020
The Chumakov Federal Scientific Center for Research and Development of Immune and Biological Products at the Russian Academy of Sciences received the Russian health ministry’s permit for clinical tests of its anti-coronavirus vaccine, the ministry’s press service said.
“Clinical trials of a vaccine against COVID-19 will begin soon in Kirov, St. Petersburg and Novosibirsk. About 3,000 volunteers are expected to take part, which is in line with the requirements of the World Health Organization and international watchdogs, and will provide a sufficient amount of scientific data for the research,” the statement says.
The ministry said the volunteers will receive all the required information about the procedure and possible risks and inconveniencies that it might entail.
After the vaccination, participants will remain in isolation in hospitals for 16 days, where their health will be monitored by doctors.
“We expect to complete the clinical trials in November,” the press service quoted Aidar Ishmukhametov, the Center’s director general, as saying.
The Chumakov Federal Scientific Center for Research and Development of Immune and Biological Products was created on the basis of the Institute of Poliomyelitis and Virus Encephalitis of the USSR Academy of Medical Sciences. Academician of the USSR Academy of Medical Sciences Mikhail Chumakov was the Institute’s founder and first director (until 1972).
Print14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Russia and the UAE can simplify the drug registration process
26 April 2024
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024
Russian drug for the treatment of viral hepatitis will be exempt from duty in Mongolia
24 April 2024